Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.

Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

Abstract: Ophthalmic device molds made from at least one water-soluble vinyl alcohol copolymer, ophthalmic devices such as ocular inserts and contact lenses and including silicone hydrogel devices formed using these molds, packaged ophthalmic devices present in a solution comprising the at least one water-soluble vinyl alcohol copolymer, and related methods are described. The methods of manufacturing ophthalmic devices can use wet demolding processes, or wet delensing processes or both wet demolding and wet delensing processes involving dissolving the molds in water or an aqueous solution.

Abstract: Silicone hydrogel ophthalmic devices, such as ocular inserts and contact lenses, formed in direct contact with molds comprising at least one vinyl alcohol copolymer and related methods are described. The at least one vinyl alcohol copolymer of the molds is a vinyl alcohol copolymer other than an ethylene-vinyl alcohol copolymer. The methods of manufacturing ophthalmic devices can use dry or wet demolding processes, or dry or wet delensing processes.

Abstract: Ophthalmic device molds made from at least one highly amorphous vinyl alcohol polymer, ophthalmic devices such as ocular inserts and contact lenses and including silicone hydrogel devices formed using these molds, and related methods are described. The methods of manufacturing ophthalmic devices can use dry or wet demolding processes, or dry or wet delensing processes.

Abstract: Ophthalmic lens molds made from at least one vinyl alcohol copolymers with high amorphous content, ophthalmic lenses including silicone hydrogel contact lenses formed using these molds, packaged ophthalmic lenses present in a solution comprising the at least one vinyl alcohol copolymer with high amorphous content, and related methods are described. The methods of manufacturing ophthalmic lenses can use wet demolding, delensing or demolding and delensing processes involving dissolving the molds in water or an aqueous solution.

Abstract: Ophthalmic device molds made from a first portion of a molding surface formed from a first polymer and a second portion of the molding surface formed from a second polymer are described. When combined, the first portion and the second portion of the molding surface form an entire molding surface suitable for molding an entire surface, such as an anterior surface or a posterior surface of an ophthalmic device. Methods of manufacturing ophthalmic devices using these molds, including contact lenses, are also described.

Abstract: Ophthalmic device molds made from at least one vinyl alcohol copolymer and having a static sessile drop contact angle of less than 70 degrees, ophthalmic devices such as ocular inserts and contact lenses and including silicone hydrogel devices formed using these molds, and related methods are described. The methods of manufacturing ophthalmic devices can use dry or wet demolding processes, or dry or wet delensing processes.

Abstract: Ophthalmic lens molds made from one or more thermoplastic polymers with average polarities from about 1% to about 7%, ophthalmic lenses including silicone hydrogel contact lenses molded using these less polar thermoplastic polymers, and related methods are described. When the molds are used to cast mold silicone hydrogel contact lenses, the resulting polymerized lens bodies have ophthalmically acceptably wettable surfaces.

Abstract: Methods of manufacturing contact lenses using ophthalmic lens molds having a molding surface comprising a thermoplastic polymer, the molding surface having a percent polarity from 3% to 20% and a surface energy from about 25 mN/m to about 40 mN/m to cast mold a polymerizable composition having a surface tension from about 20 mN/m to about 25 mN/m, wherein a surface energy differential of the surface tension of the polymerizable composition less the surface energy of the molding surface less than or equal to zero (0); and silicone hydrogel contact lens bodies so manufactured are described.

Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

Abstract: Compounds of formula I in free or salt form, wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Abstract: An emergency anti-hypothermia system has a thermally insulating vest that is sufficiently portable to be carried for emergency use in a pocket, purse, backpack, compartment of a vehicle, ski pole or other location. The vest provides thermal insulation by being made with thermally insulating air impervious material that also provides for its inflation. The inflating air also provides insulation as, preferably, does thermal radiation reflective material on inwardly facing surfaces of the vest, preferably inwardly facing surfaces of outer layers of inflated chambers about the vest, the multiplicity of the chambers about the vest reducing convection heat transfer therewithin. The vest thus preferably provides thermal insulation by anti-conduction, anti-radiation and anti-convection in a highly portable system.

Abstract: There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF) receptor antagonists Formula (I).

Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

Abstract: A lifting grab for grabbing and lifting drums and/or other objects includes: a lifting point having two or more lifting arms radiating therefrom, the arms each having rim engaging elements, at least one arm is an articulated arm movable between engaging and non-engaging positions. A drum can be grabbed by initially attaching the engaging elements of the non-articulated arms to the rim, the at least one articulated arm then brought into the rim engaging position for attachment to the object or rim. Applying an upward or lifting force to the lifting point causes the rim engaging elements of all lifting arms to forcibly grab the object or rim of the drum, and whereby on releasing the lifting force, the at least one articulated arm is first disengaged from the rim thereby also relaxing the grip of the non-articulated arms wherein the drum or object can be released from the grab.

Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

Abstract: The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R1, R2, Ar?, A and Y are defined in the description, to compositions and use of the compounds in the treatment of inflammatory and allergic conditions.

Abstract: The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R1, R2, Ar?, A and B are defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.